{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.22","upperLimit":"53.4","value":"14.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Average tumor Ribociclib concentrations will be compared to plasma concentrations. The mean tumor-to-plasma ratio of Ribociclib at the time of surgery will be described.","dispersionType":"Full Range","groups":[{"description":"Patients who are undergoing surgery also receive ribociclib PO QD on days 7-10 at 120 mg/m2/day before surgery","id":"OG000","title":"Surgical"}],"paramType":"MEDIAN","populationDescription":"Patients who were enrolled on surgical study and with tumor and matching plasma samples available.","reportingStatus":"POSTED","timeFrame":"Surgical study: Prior to starting ribociclib (day -7 or -10), prior to ribociclib dose on days -5 & -2, day 0, and at the time of surgery","title":"Average Tumor and Plasma Concentrations of Ribociclib for the Surgical Study","type":"PRIMARY","unitOfMeasure":"ratio"}